26 results about "Corneal epithelium" patented technology

Provided is a medical apparatus for predicting myopic regression. The medical apparatus for predicting myopic regression can be configured to predict at least one of a probability of myopic regression and whether myopic regression will occur from numerical data including a refractive power, a corneal curvature, an eye axial length, a photopic pupil size, a mesopic pupil size, a corneal diameter, a corneal thickness, a corneal epithelial thickness, a high-order aberration, a visual acuity, an intraocular pressure, a sex, and an age using a machine learning processor.

The disclosure relates to formulations and methods for the in vitro testing of ocular irritants. It was discovered that adding an antioxidant formulation to in vitro ocular irritation tests, including for example, a biochemical ocular irritation test, a reconstituted human corneal epithelium (RhCE) ocular irritation test and an excised eye depth of injury (Dol) test, substantially reduces the rate of false positives without diminishing test sensitivity, resulting in more accurately predicting ocular irritancy of test substances. More particularly, the disclosed method employs relatively high physiologic concentrations of one or more antioxidants that are normally present in tears. In a variation, much higher concentrations of one or more antioxidants may provide protection against in vivo exposure to ocular irritants.

The present invention provides a use of a functional thylakoid extract, particularly in combination with a physiologically acceptable carrier, for medical purposes in wound healing. The thylakoid extract can be used to treat wounds in the skin or mucosa, such as open wounds or wounds caused by physical trauma. The thylakoid extract can be used to increase the production or level of GM-CSF growth factor and / or G-CSF growth factor in the skin or mucosa of a subject after wounding (e.g., wounds in the skin, mucosa, or corneal epithelium).

A method implemented in an ophthalmic surgical laser system for forming a corneal flap in a patient's eye with improved bubble management. The flap includes a horizontal bed and a vertical or near vertical side cut around the periphery of the bed except for an uncut hinge area. The side cut has a bubble barrier layer that can prevent bubbles formed by the laser-tissue interaction from escaping into an interface between the corneal and the patient interface lens. In some embodiments, the bubble barrier layer is a thin uncut layer, located in the epithelium of the cornea, that separates the side cut into two portions. In other embodiments, the side cut does not reach the anterior corneal surface, leaving an uncut bubble barrier layer located with the epithelium. In other embodiments, an additional side cut portion is formed through the uncut bubble barrier layer as the last step.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition, a preparation method thereof and application of the traditional Chinese medicine composition in preparation of medicines for treating ophthalmic diseases. The traditional Chinese medicine composition provided by the invention is prepared from the following raw materials: flos chrysanthemi, concha haliotidis, semen cassiae torae, honey-fried licorice root and a component A, wherein the component A is selected from at least one of herba schizonepetae, radix puerariae and herba menthae. The composition has the effects of removing heat from the liver and purging heat, and treating red and astringent eye pain, and experiments show that the composition can improve the tear secretion amount, prolong the tear film rupture time and / or protect the corneal epithelium. The traditional Chinese medicine composition can be clinically used for treating dry eyes, asthenopia, keratoconjunctivitis, cataract and vitreous opacity.

This invention discloses a blueberry anthocyanin nutritional solid composition for relieving eye discomfort. The composition comprises blueberry anthocyanin solid powder, algal oil powder, zinc gluconate, and selenium-enriched yeast, and may optionally contain lipid nutrients containing gamma-linolenic acid, as well as food additives and excipients. Oral administration of this composition provides the body with various nutritional supports related to ocular surface function and ocular moisture, helping to maintain tear secretion levels, improve tear film stability, and support the normal physiological state of the corneal epithelium, thereby relieving eye dryness and discomfort caused by environmental stimuli or increased eye strain. Animal experiments showed that after 14 days of continuous administration of the composition, experimental mice exhibited a significantly increased tear secretion volume compared to the control group without the composition, with an increase of approximately 165%. Corneal fluorescein staining scores were also significantly reduced, indicating improved ocular surface condition and significantly enhanced eye comfort.

During use, the contact lens (10) forms a hollow space between its concave inner surface and the convex outer surface of the eye, and due to the presence of multiple microprotrusions (13), the contact lens (10) contacts the corneal epithelium only on a portion of its inner surface facing the eye, and the microprotrusions (13) allow the contact lens (10) to be raised a few micrometers relative to the corneal surface.

The present application provides a medicine for treating ocular surface and corneal epithelial diseases, which has fibroblast growth factor 5 as an effective component. The medicine has the effects of promoting corneal epithelial repair and treating ocular surface diseases caused by fibroblast growth factor 5 (FGF5) gene mutation, and has no toxic side effects.

The application discloses a kind of drug composition of synergistic targeting MMP-9 path and STING path and application thereof, belong to the technical field of ophthalmic drugs.The drug composition includes the final concentration 5~90 μM of Marimastat, the final concentration 2.5~10 μM of SN-011, the final concentration 0.1 vol % of DMSO and sterile PBS buffer solution.The drug composition of the application can efficiently, safely treat moderate to severe dry eye, effectively improve tear film stability, repair corneal epithelial barrier, inhibit ocular surface chronic inflammation, while reducing the risk of disease recurrence.

1. Name of the Design Product: Dry Eye Laser Acupuncture Therapeutic Instrument. 2. Use of the Design Product: It is used to directly, focus or expand the beam of a low-intensity laser to irradiate the surface or deep part of the acupoint area of the acupoints, so as to improve the subjective symptoms of dry eye patients, increase the height of the tear river, extend the average tear film break-up time, and promote the repair of corneal epithelium. 3. Design Key Points of the Design Product: Lies in the shape. 4. Picture or Photograph Most Indicating the Design Key Points: Perspective View 1. 5. It has been expressed in Perspective View 2, so the bottom view is omitted.

The invention relates to a method for providing control data for an ophthalmic laser (12) of a treatment device (10). The method comprises, as steps: determining parameters of an epithelial layer and a stroma of a cornea (16); determining a correction profile (14) for correcting a refractive error of the cornea (16); determining data of a virtual postoperative cornea expected by treating the cornea (16) with the correction profile (14), wherein the data of the virtual postoperative cornea are determined as a function of an epithelial layer model in which epithelial regrowth of the cornea is modeled, wherein model parameters of the epithelial layer model are provided from statistics of epithelial regrowth processes of a given population group;a determination of a correction difference between an originally planned correction and a virtually achieved correction; an adjustment of the correction profile (14) depending on the correction difference; and a provision of the control data for the ophthalmic laser (12) that includes the adjusted correction profile.;

The invention discloses an ophthalmic preparation / composition which comprises a single cinnamic acid compound or a derivative thereof, a single catechin compound or a derivative thereof, or a combination of the cinnamic acid compound and the catechin compound, and an acceptable excipient, the formulations / compositions are useful for the treatment / clearance / alleviation of conditions associated with cataract, intraocular pressure and glaucoma, lenticular degeneration, corneal epithelial hyperplasia and liquefaction, and inflammation.

This invention belongs to the technical field of biomedicine and discloses the application of a composition comprising neo-agar oligosaccharides and astaxanthin in the preparation of formulations for the treatment of dry eye syndrome, as well as the formulation of in-situ gel eye drops and its preparation method. The composition provided by this invention specifically comprises neo-agar oligosaccharides and astaxanthin, which together constitute an organic whole, synergistically contributing to excellent ocular surface retention time and penetration efficiency. It can effectively inhibit the activation of core inflammatory pathways at low doses, reduce inflammatory cell infiltration in ocular surface tissues, promote goblet cell proliferation and epithelial repair, increase tear secretion, and improve corneal epithelial integrity. This achieves multiple effects, including anti-inflammatory properties, increased tear secretion, reduced corneal damage, promotion of ocular surface tissue repair, and improvement of corneal epithelial integrity. Furthermore, the composition exhibits excellent ocular surface biocompatibility and has very promising application prospects in the preparation of formulations for the treatment of dry eye syndrome.

The invention relates to the technical field of medical supplies for ophthalmology, and particularly discloses a cornea surface protective agent based on a compound polysaccharide synergistic effect and a preparation method of the cornea surface protective agent. The protective agent comprises chitosan quaternary ammonium salt, trehalose and recombinant human collagen as core active components, and a specific buffer system is supplemented. Through the specific proportioning combination of the core components, the protective agent can quickly form a stable and light-transmitting protective film on the cornea surface, and provides the comprehensive effects of long-acting moisturizing, epithelial repair promotion and inflammation resistance. Experiments show that the moisturizing time of the protective agent can reach more than 90 minutes, the light transmittance exceeds 98%, and corneal epithelium injury repair can be remarkably accelerated. The invention further provides a preparation method of the protective agent, and the preparation method is simple in process and suitable for industrial production.

The invention discloses a water-soluble cellulose derivative-silk fibroin artificial tear with the characteristics of long-acting retention and no irritation and a preparation method thereof. The artificial tear comprises a water-soluble cellulose derivative, silk fibroin, an osmotic pressure regulator, a pH regulator and water. After the water-soluble cellulose derivative is dissolved, a transparent viscous colloid can be formed, a protective film can be formed on the ocular surface, a tear film is stabilized, tear evaporation is delayed, friction is reduced, and dryness and foreign body sensation are rapidly relieved. The polar group of the silk fibroin and the silk fibroin form a stable network through a hydrogen bond, eyelid shearing and tear erosion are resisted, the bioavailability of the silk fibroin is improved, and the silk fibroin has the effects of resisting inflammation and promoting corneal epithelium repair. The osmotic pressure regulator and the pH regulator are cooperated, so that the osmotic pressure and the pH value of the artificial tear approach to those of human tears, the ocular surface is prevented from being stimulated, and the medication comfort and compliance are improved. The artificial tear can quickly relieve the dry eye symptom, realizes long-acting cornea repair, and provides a new strategy for development of a high-efficiency long-acting eye drug delivery system.

Keratoconjunctivitis sicca is a general term of a plurality of diseases which are accompanied by eye discomfort and (or) ocular surface tissue lesion characteristics and are caused by tear quality or quantity abnormality or dynamic abnormality caused by any reason, and belongs to the field of chronic keratoconjunctivitis in western medicine. The common symptoms comprise eye dryness, easy fatigue, eye itching, foreign body sensation, burning pain, secretion viscosity, wind afraid, photophobia, lacrimation and external stimulation sensitivity; the two eyes of a patient with serious diseases in the later stage are red and swollen, hyperemia and keratinization, corneal epithelium exfoliation and filament adhesion exist, keratoconjunctival lesion can be caused if the patient is injured for a long time, and the continuous development of the keratoconjunctival lesion possibly causes irreversible influence on vision. The traditional Chinese medicine composition is characterized by being prepared from the following raw material medicines in parts by mass: 100 to 1000 parts of radix rehmanniae, 100 to 1000 parts of radix ophiopogonis, 100 to 1000 parts of herba dendrobii, 100 to 1000 parts of bulbus lilii, 100 to 1000 parts of radix polygonati officinalis and 200 to 500 parts of flos chrysanthemi. Corresponding auxiliary materials can also be added into the traditional Chinese medicine composition to prepare clinically common tablets, granules and oral dosage forms.

Formulations, are used for eye treatments, e.g., cross-linking treatments. For example, a therapeutic formulation includes a photosensitizer and delivery agent(s), wherein the delivery agent(s) include at least one of: anesthetic agent(s), analgesic agent(s), tonicity agent(s), or shear-thinning, or viscosity-increasing agent(s). In another example, a method includes applying preparatory formulation(s) to increase a permeability of a corneal epithelium, and applying therapeutic formulation(s) to the epithelium, where the preparatory formulation(s) include zinc metalloproteinase, copper metalloproteinase, papain, bromelain, actinidin, ficain, N-acetylcysteine, ambroxol, carbocisteine, and / or erdosteine. In yet another example, a method includes applying therapeutic formulation(s) to a corneal epithelium to deliver the therapeutic formulation(s) to a stroma, and applying enhancement formulation(s) to the epithelium in response to applying the therapeutic formulation(s), where: the enhancement formulation(s) remove the therapeutic formulation(s) from the epithelium; close tight junctions of the epithelium; promote oxidation for the therapeutic agent(s); and / or further deliver the therapeutic formulation(s) to the stroma.

The invention discloses a preoperative corneal epithelium thickness measuring method based on slit lamp CCD three-dimensional reconstruction, and relates to the technical field of slit lamp microscope and CCD imaging, and the method comprises the steps: extracting information from an electronic medical record based on template initialization driven by the medical history of a patient, and automatically loading an individualized epithelium thickness initial template; a modified slit lamp CCD is used for multi-angle synchronous acquisition, tear film stability is monitored in real time, and high-fidelity epithelium point cloud data is generated; an elastic deformation-Kalman coupling fitting technology is adopted, a template is adaptively adjusted according to the point cloud residual error and the curvature gradient, a high-confidence-coefficient thickness grid is generated through curvature continuity filtering and optical reprojection correction, and an error distribution label is added to each pixel; the data is packaged and then pushed to a surgical navigation platform, and when the confidence coefficient is low, re-collection is automatically prompted; the accuracy, traceability and reliability of measurement data are improved, and robust support is provided for early lesion screening and preoperative planning.

The application provides application of KGF-2 in treatment of dry eye, and proves that KGF-2 can improve the basic tear secretion of dry eye mice in a dose-dependent manner, prolong the tear film break-up time, reduce the corneal epithelium and corneal nerve injury, and can reduce the expression levels of inflammatory factors such as tear gland MMP-3, MMP-9 and TNF alpha, and improve the tear secretion function of the tear gland.

The invention discloses a therapeutic corneal contact lens with a far infrared function, and belongs to the technical field of medical precision instruments. A far infrared nanometer material is embedded in a lens body of the contact lens. A far-infrared nano material layer is embedded between the two layers of lens bodies in contact with the palpebral conjunctiva and the bulbar conjunctiva; or the far-infrared nano material is dispersed in the lens body, so that far-infrared energy can be stably released, regeneration and repair of corneal epithelium tissues are actively promoted, physical protection is provided, and the problem of corneal epithelium repair of a patient suffering from xerophthalmia is effectively solved.

The disclosure relates to formulations and methods for the in vitro testing of ocular irritants. It was discovered that adding an antioxidant formulation to in vitro ocular irritation tests, including for example, a biochemical ocular irritation test, a reconstituted human corneal epithelium (RhCE) ocular irritation test and an excised eye depth of injury (DoI) test, substantially reduces the rate of false positives without diminishing test sensitivity, resulting in more accurately predicting ocular irritancy of test substances. More particularly, the disclosed method employs relatively high physiologic concentrations of one or more antioxidants that are normally present in tears. In a variation, much higher concentrations of one or more antioxidants may provide protection against in vivo exposure to ocular irritants.

Generation of treatment recommendations for topographic-based excimer laser surgical procedures is described that includes generating accurate cylinder compensation and spherical compensation values that are adjusted to compensate for unique characteristics of topographic-based excimer laser surgical systems. Generating treatment recommendations generally includes determining a topographic vector, a posterior astigmatism vector and an anterior astigmatism vector, and generating an internal astigmatism vector using the topographic vector, the posterior astigmatism vector, the anterior astigmatism vector, and a manifest astigmatism vector. In embodiments, the cylinder compensation is generated using multiple vectors while subtracting the internal astigmatism vector and the posterior astigmatism vector which remain in the eye after treatment, and the spherical compensation is generated using an initial spherical compensation modified by addback modifiers and a regression analysis nomogram. In procedures where the corneal epithelium is removed, an epithelial refractive vector is determined from an epithelial thickness / topography map and added to the other vectors.

This invention belongs to the field of biopharmaceuticals, specifically relating to the use of bone morphogenetic protein-4 (BMP4) in the preparation of drugs for treating corneal diseases. BMP4 has a mild growth-promoting effect on corneal epithelium and stroma, and can treat CNV caused by epithelial damage. BMP4 can also be used as a drug to repair epithelial damage. BMP4 is used to inhibit corneal inflammatory response and plays an important role in the corneal damage repair process. Its administration method is convenient and non-invasive, and it is easy to promote.

An ophthalmic formulation comprising an animal aqueous humor extract, a preparation method therefor, and use thereof. The aqueous humor is similar in composition to serum, and has lower metabolites, thereby enabling protection of the starvation-induced corneal epithelium. The ophthalmic formulation comprising the animal aqueous humor extract has the effect of treating xerophthalmia.

Disclosed in the present application are a method and an apparatus for measuring an ocular axis length, an electronic device, and a storage medium. The method for measuring an ocular axis length comprises: acquiring at least one OCT image of an ocular tissue with an imaging range covering a range from a cornea to a retina of an eye to be measured; performing position recognition on the at least one OCT image to obtain a plurality of target positions, wherein the plurality of target positions comprise a corneal epithelial vertex position and a retinal macular fovea position; and determining an ocular axis length of said eye on the basis of the plurality of target positions.

The invention discloses ultra-small gold nanoparticles capable of penetrating a blood-eye barrier and a preparation method and application of the ultra-small gold nanoparticles. The ultra-small gold nanoparticles comprise an atomic precision gold nanocluster (Au22) core; the ligand is covalently modified on the surface of the Au22 core through an Au-S bond; the ligands are glutathione (GSH), and the number of the ligands is 10 to 16; the sequence of the cell-penetrating peptide CR8 is CRRRRRRR, a part of GSH ligands are replaced by Au-S bonds, and the modification quantity is 2-8 CR8 molecules / Au22 clusters. Safety evaluation proves that the preparation has no toxic effect on corneal epithelium and retina nerve cells. Through collaborative design of the atomic precision metal cluster and the cell-penetrating peptide, the technical problem of non-invasive treatment of posterior ocular segment diseases is innovatively solved, and a safe and efficient new treatment strategy is provided for age-related macular degeneration, diabetic retinopathy and other ROS-mediated fundus diseases.